← feed

Is NCT03162926 results overdue?

Yes — results are overdue. Primary completion was 2018-02-15; the FDAAA-801 reporting deadline (2019-02-15) passed 2729 days ago and no results are posted on ClinicalTrials.gov.

A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus

NCT IDNCT03162926 ↗
SponsorViaCyte (INDUSTRY)
PhasePHASE1
StatusCOMPLETED
Primary completion2018-02-15 (ACTUAL)
Reporting deadline2019-02-15 (completion + 365d)
Days overdue2729
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 1ea54fd4e9d6de5e… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03162926. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →